Viking Therapeutics Inc

NASDAQ: VKTX
$52.59
+$0.96 (+1.9%)
Closing Price on November 22, 2024

VKTX Stock Chart and Intraday Price

VKTX Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 12340 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 8,563.59M USD
Shares Outstanding 100,488,000
Viking Therapeutics, Inc. is a San Diego-based biopharmaceutical company focused on developing innovative treatments for metabolic and endocrine disorders. Its leading drug, VK2809, targets non-alcoholic steatohepatitis and NAFLD with a novel approach, aiming for efficacy and safety. Viking is also advancing VK5211 for hip fracture recovery, VK0612 for type 2 diabetes, VK2735 for metabolic diseases, and VK0214 for X-linked adrenoleukodystrophy, showcasing a diverse pipeline aimed at addressing significant unmet medical needs.

VKTX Articles

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 466.14% and currently trading at $748.50. The company has been around since 1876 and the...
Jim Cramer is probably the closest thing we have to stock market superstar influencer. The host of CNBC’s “Mad Money” show is entertaining and popular with a broad swath of investors who like...
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX), for example. Now trading at $57.80, we strongly believe it could easily rally...
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry. The...
Thursday's top analyst upgrades and downgrades included America Movil, Avis Budget, Box, Chevron, Coty, Five9, Regeneron Pharmaceuticals, SeaWorld Entertainment, Twilio, Viking Therapeutics and Xylem.
Friday's top analyst upgrades and downgrades included Boston Scientific, Charles Schwab, eBay, Electronic Arts, FedEx, Meta Platforms, Norfolk Southern, Progressive, Roku, ServiceNow, Viking...
Wednesday's top analyst upgrades and downgrades included Aflac, Capri, Coterra Energy, First Republic Bank, PDD, Range Resources, Stanley Black & Decker, Starwood Property Trust, VFC, Viking...
Thursday's top analyst upgrades and downgrades included Abbott Laboratories, Carnival, Deere, Delta Air Lines, DexCom, Enovix, First Republic Bank, GitLab, Hartford Financial Services, Interpublic...
Wednesday's top analyst upgrades and downgrades included Array Technology, Blink Charging, Carnival, Carrier Global, DocuSign, Fox, Marathon Petroleum, Occidental Petroleum, PagSeguro Digital,...
Thursday's top analyst upgrades and downgrades included Antero Resources, Carnival, CF Industries, ChargePoint, Enphase Energy, Howmet Aerospace, Meta Platforms, New York Community Bancorp, Nike,...
Tuesday's top analyst upgrades and downgrades included Ally Financial, Amgen, Baidu, Bilibili, Bill.com, Coinbase Global, Eli Lilly, GE Healthcare Technologies, JPMorgan Chase, Merck, Moderna,...
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
Monday's top analyst upgrades and downgrades included Altria, Amazon.com, Apple, Axalta Coating Systems, Comcast, Etsy, Intel, McDonald's and Medical Properties Trust.
Thursday's top analyst upgrades and downgrades included Blackstone, Carlyle, FedEx, Home Depot, Palo Alto Networks, Payoneer, Poshmark, Take-Two Interactive Software, Trade Desk, Twitter and ZoomInfo...
Biotechnology was a huge laggard last year, but Truist Securities is out with its five top picks for 2022 that could see some sensational performance this year. Portfolio managers favor these...